Egis is one of the leading generic pharmaceutical companies in Hungary and in the region as well. We are a vertically integrated company, meaning our activities incorporate all areas of the pharmaceutical value chain: 

·       research and development (active ingredients and finished products),

·       manufacturing (active ingredients and finished products)

·       sales (active ingredients and finished products).

Our active ingredients and finished products are available in 103 countries. the network of our subsidiaries and representative offices covers 17 countries, in other countries our products are available through our partners.  

19% of our sales are in Hungary and 81% abroad.

All R&D and manufacturing take place in Hungary.

We have three production sites: 

·       two in Budapest (Keresztúri út and Bökényföldi út) and

·       one in Körmend.

Our commercial center is in Budapest on Lehel út.

Diseases of

• Cardiovascular and

• Central nervous system

and we also provide modern treatment solutions in the fields of 

·       diabetology,

dermatology and wound care.

In the 2023–2024 business year:

• 207 million boxes of medicines sold

• 6.6 billion tablets/capsules produced

• 1,050 tons of active ingredients/intermediates manufactured

More than 33 million patients worldwide take Egis medicines each year.

 We have 4,600 employees, more than 3,500 of them in Hungary.

The new, modern active ingredient manufacturing facility

·       is at our Keresztúri út site

·       is a brownfield investment,

·       was fully financed by Egis, 30 billion HUF.

·       has a “twin plant” with the same technology, recently opened in Normandy.

A new multi-level production building

• A high-bay warehouse with capacity for 900 pallets

            • A renewed service building (utilities, process control, QC laboratory, social areas, offices)

• A new tank farm

Altogether, this investment covers about 7,000 m².

About 1 year of planning and 4 years of construction. More than 200 Egis colleagues contributed to the project.

The active ingredient of a globally market-leading Servier Group medicine, used to treat venous diseases. Together, the plants in Normandy and Budapest will provide the necessary capacity and will double current production volumes.

Yes, but in smaller amounts and with older technology. The new plant uses a modern, more efficient, and more environmentally friendly production process.

For more than 70 years. In recent years, we have produced around 1,000 tons of active ingredients and intermediates annually—about the weight of 180 elephants.

Yes. Once the new plant reaches full capacity, approximately 80 people are expected to work there. About three-quarters of this number will be new employees, while roughly 25% will be current colleagues who were previously involved in producing this active ingredient. Thanks to the new technology, they have also gained new knowledge, which means the expansion offers significant development opportunities for them.

While many European companies outsourced or stopped making active ingredients, Egis modernized and strengthened its production. This capability significantly improves our international competitiveness.

According to the plans, the first commercial batches will be ready in December (but their release is expected later).

The investment was entirely financed from the company’s own resources.